A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Key Insights Amgen's estimated fair value is US$537 based on 2 Stage Free Cash Flow to Equity Amgen's US$309 share...